475 related articles for article (PubMed ID: 17550987)
1. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study.
Horakova D; Cox JL; Havrdova E; Hussein S; Dolezal O; Cookfair D; Dwyer MG; Seidl Z; Bergsland N; Vaneckova M; Zivadinov R
J Neurol Neurosurg Psychiatry; 2008 Apr; 79(4):407-14. PubMed ID: 17550987
[TBL] [Abstract][Full Text] [Related]
2. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study.
Horakova D; Dwyer MG; Havrdova E; Cox JL; Dolezal O; Bergsland N; Rimes B; Seidl Z; Vaneckova M; Zivadinov R
J Neurol Sci; 2009 Jul; 282(1-2):112-9. PubMed ID: 19168190
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein E ε4-positive multiple sclerosis patients develop more gray-matter and whole-brain atrophy: a 15-year disease history model based on a 4-year longitudinal study.
Horáková D; Kýr M; Havrdová E; Doležal O; Lelková P; Pospíšilová L; Bergsland N; Dwyer MG; Cox JL; Hussein S; Seidl Z; Vaněčková M; Krásenský J; Zivadinov R
Folia Biol (Praha); 2010; 56(6):242-51. PubMed ID: 21324265
[TBL] [Abstract][Full Text] [Related]
4. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
[TBL] [Abstract][Full Text] [Related]
5. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
[TBL] [Abstract][Full Text] [Related]
6. Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis.
Battaglini M; Giorgio A; Stromillo ML; Bartolozzi ML; Guidi L; Federico A; De Stefano N
J Neurol Sci; 2009 Jul; 282(1-2):55-60. PubMed ID: 19286193
[TBL] [Abstract][Full Text] [Related]
7. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
Zivadinov R; Locatelli L; Cookfair D; Srinivasaraghavan B; Bertolotto A; Ukmar M; Bratina A; Maggiore C; Bosco A; Grop A; Catalan M; Zorzon M
Mult Scler; 2007 May; 13(4):490-501. PubMed ID: 17463072
[TBL] [Abstract][Full Text] [Related]
8. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.
Reggio E; Nicoletti A; Fiorilla T; Politi G; Reggio A; Patti F
J Neurol; 2005 Oct; 252(10):1255-61. PubMed ID: 15940386
[TBL] [Abstract][Full Text] [Related]
9. Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years.
Zivadinov R; Bergsland N; Dolezal O; Hussein S; Seidl Z; Dwyer MG; Vaneckova M; Krasensky J; Potts JA; Kalincik T; Havrdová E; Horáková D
AJNR Am J Neuroradiol; 2013 Oct; 34(10):1931-9. PubMed ID: 23578679
[TBL] [Abstract][Full Text] [Related]
10. Development of gray matter atrophy in relapsing-remitting multiple sclerosis is not gender dependent: results of a 5-year follow-up study.
Dolezal O; Gabelic T; Horakova D; Bergsland N; Dwyer MG; Seidl Z; Krasensky J; Ramasamy DP; Vaneckova M; Havrdova E; Zivadinov R
Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S42-8. PubMed ID: 24321154
[TBL] [Abstract][Full Text] [Related]
11. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
[TBL] [Abstract][Full Text] [Related]
12. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis.
Barkhof F; de Jong R; Sfikas N; de Vera A; Francis G; Cohen J;
Mult Scler; 2014 Nov; 20(13):1704-13. PubMed ID: 24812043
[TBL] [Abstract][Full Text] [Related]
13. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta.
Paolillo A; Pozzilli C; Giugni E; Tomassini V; Gasperini C; Fiorelli M; Mainero C; Horsfield M; Galgani S; Bastianello S; Buttinelli C
Eur J Neurol; 2002 Nov; 9(6):645-55. PubMed ID: 12453081
[TBL] [Abstract][Full Text] [Related]
14. Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years.
Turner B; Lin X; Calmon G; Roberts N; Blumhardt LD
Mult Scler; 2003 Feb; 9(1):21-7. PubMed ID: 12617263
[TBL] [Abstract][Full Text] [Related]
15. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
[TBL] [Abstract][Full Text] [Related]
16. Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort.
Kalincik T; Horakova D; Dolezal O; Krasensky J; Vaneckova M; Seidl Z; Havrdova E
Clin Neurol Neurosurg; 2012 Sep; 114(7):940-6. PubMed ID: 22402204
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
18. Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment.
Lus G; Romano F; Scuotto A; Accardo C; Cotrufo R
Eur Neurol; 2004; 51(1):15-20. PubMed ID: 14631124
[TBL] [Abstract][Full Text] [Related]
19. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
Arnold DL; Calabresi PA; Kieseier BC; Liu S; You X; Fiore D; Hung S
BMC Neurol; 2017 Feb; 17(1):29. PubMed ID: 28183276
[TBL] [Abstract][Full Text] [Related]
20. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Kappos L; Wiendl H; Selmaj K; Arnold DL; Havrdova E; Boyko A; Kaufman M; Rose J; Greenberg S; Sweetser M; Riester K; O'Neill G; Elkins J
N Engl J Med; 2015 Oct; 373(15):1418-28. PubMed ID: 26444729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
